专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050180947A1 Novel application of vaccination against TNF-alpha 审中-公开
标题翻译：针对TNF-α的新型应用
公开(公告)号：US20050180947A1
公开(公告)日：2005-08-18
申请号：US10939107
申请日：2004-09-10
申请人： Hans Pedersen , Bjarke Ebert , Louise Pedersen , Peter Rasmussen
发明人： Hans Pedersen , Bjarke Ebert , Louise Pedersen , Peter Rasmussen
IPC分类号： A61K38/19 , A61K39/00 , A61K48/00 , A61P25/00 , C07K16/24
CPC分类号： C07K16/241 , A61K38/191 , A61K39/0005 , A61K2039/505 , A61K2039/55577
摘要： The present invention relates to novel medical applications of down-regulation of tumour necrosis factor α (TNF-α) activity, especially novel applications of active immunization against TNF-a in order to reduce or alleviate pain. In particular, the present invention discloses novel methods for treating or ameliorating neuropathic pain.
摘要翻译：本发明涉及肿瘤坏死因子α（TNF-α）活性下调的新型医学应用，特别是针对TNF-α的主动免疫的新型应用以减轻或缓解疼痛。特别地，本发明公开了治疗或改善神经性疼痛的新方法。

2. 发明申请

US20050288371A1 Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis 审中-公开
标题翻译：治疗神经性疼痛，纤维肌痛或类风湿关节炎
公开(公告)号：US20050288371A1
公开(公告)日：2005-12-29
申请号：US11020630
申请日：2004-12-22
申请人： Bjarke Ebert , Connie Sanchez
发明人： Bjarke Ebert , Connie Sanchez
IPC分类号： A61K31/195
CPC分类号： A61K31/195 , A61K31/437 , Y02A50/401
摘要： The present invention relates to the use of gaboxadol for the preparation of medicaments useful for the treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis.
摘要翻译：本发明涉及加波沙朵用于制备可用于治疗神经性疼痛，纤维肌痛或类风湿性关节炎的药物的用途。

3. 发明申请

US20090143435A1 GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity 审中-公开
标题翻译： GABA增强剂治疗与减少的神经甾体活性有关的疾病
公开(公告)号：US20090143435A1
公开(公告)日：2009-06-04
申请号：US12163883
申请日：2008-06-27
申请人： Bjarke Ebert , Peter Hongaard Andersen
发明人： Bjarke Ebert , Peter Hongaard Andersen
IPC分类号： A61K31/4375 , A61P25/00
CPC分类号： A61K31/197 , A61K31/195 , A61K31/4172 , A61K31/42 , A61K31/437 , A61K31/4535
摘要： The invention provides the use of a non-steroid compound which acts on the GABA receptor for the treatment of disorders relating to reduced neurosteroid activity. The non-steroid compounds may be GABA agonists, GABA uptake inhibitors or enhancers of GABAergic activity.
摘要翻译：本发明提供了作用于GABA受体的非类固醇化合物用于治疗与降低的神经甾体活性有关的疾病的用途。非类固醇化合物可以是GABA激动剂，GABA摄取抑制剂或GABA能活性的增强剂。

4. 发明申请

US20090048288A1 METHOD OF TREATING STRESS-MEDIATED DEPRESSION 审中-公开
标题翻译：处理压力介质渗透的方法
公开(公告)号：US20090048288A1
公开(公告)日：2009-02-19
申请号：US12187865
申请日：2008-08-07
申请人： Bjarke Ebert , Torsten Meldgaard Madsen
发明人： Bjarke Ebert , Torsten Meldgaard Madsen
IPC分类号： A61K31/437 , C12Q1/28 , C12Q1/52 , C12Q1/37 , G01N33/68 , A61P25/00 , A61P25/24
CPC分类号： G01N33/6893 , A61K31/437 , G01N2800/304 , G01N2800/52
摘要： The present invention relates to a method for the treatment of depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers in said patient is increased or abnormal. The present invention also relates to a method for the treatment of stress-mediated depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers is increased or abnormal in said patient. The present invention also relates to a method for the treatment of depression or the amelioration of one or more depressive symptoms comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the clinical presentation of one or more symptoms of depression are the physiological effect of a general medical condition. Furthermore the present also relates to a method for testing the therapeutic effectiveness of a compound in the treatment of depression or reducing the symptoms of depression comprising measuring the amount of one or more inflammatory markers in a sample from a patient before said compound is administered to the patient and comparing with the amount of said one or more inflammatory markers in a sample from the same patient after administration of said compound to the patient.
摘要翻译：本发明涉及一种治疗抑郁症的方法，包括向患者施用治疗有效量的加波沙朵，其中所述患者中一种或多种炎性标志物的水平升高或异常。本发明还涉及治疗应激介导的抑郁症的方法，包括向患者施用治疗有效量的加波沙朵，其中所述患者中一种或多种炎性标志物的水平升高或异常。本发明还涉及一种治疗抑郁症或改善一种或多种抑郁症状的方法，包括向患者施用治疗有效量的加波沙朵，其中一种或多种抑郁症状的临床表现是生理作用一般医疗状况。此外，本发明还涉及一种用于测试化合物治疗抑郁症或减轻抑郁症状的治疗有效性的方法，该方法包括在将所述化合物给药至所述化合物之前测量来自患者的样品中的一种或多种炎症标志物的量并将所述化合物给予患者后的来自同一患者的样品中所述一种或多种炎性标志物的量进行比较。

5. 发明申请

US20080269278A1 Treatment of Impaired Respiratory Function with Gaboxadol 审中-公开
标题翻译：加波沙朵治疗呼吸功能受损
公开(公告)号：US20080269278A1
公开(公告)日：2008-10-30
申请号：US10599504
申请日：2005-03-31
申请人： Jonas Lundahl , Bjarke Ebert , Jan Hedner
发明人： Jonas Lundahl , Bjarke Ebert , Jan Hedner
IPC分类号： A61K31/437 , A61P11/00
CPC分类号： A61K31/424
摘要： The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day.
摘要翻译：本发明涉及一种治疗患有睡眠呼吸暂停（例如中枢性睡眠呼吸暂停或阻塞性睡眠呼吸暂停）的人类患者的受损呼吸功能的方法，包括每天向所述患者施用有效量的加波沙朵。

6. 发明申请

US20070203216A1 METHOD OF TREATING INFLAMMATORY DISEASES 审中-公开
标题翻译：治疗炎症疾病的方法
公开(公告)号：US20070203216A1
公开(公告)日：2007-08-30
申请号：US11673898
申请日：2007-02-12
申请人： Bjarke Ebert , Timothy Bonnert , Peter Hutson , Richard Rutter
发明人： Bjarke Ebert , Timothy Bonnert , Peter Hutson , Richard Rutter
IPC分类号： A61K31/4172 , A61K31/195
CPC分类号： A61K31/437 , A61K31/195 , A61K31/197 , A61K31/4172 , A61K31/42 , A61K31/4409 , A61K31/4535 , A61K45/06 , A61K2300/00
摘要： The present invention relates to the use of gaboxadol, or a combination of gaboxadol and one or more anti-inflammatory compounds, for the treatment of an inflammatory disease. The present invention further relates to a pharmaceutical composition comprising gaboxadol and one or more anti-inflammatory compounds. The present invention further relates to a method of treating a disease wherein one or more inflammatory markers are increased, comprising administering to a subject in need thereof a therapeutically effective amount of a compound that enhances GABAA-ergic neurotransmission.
摘要翻译：本发明涉及加波沙朵或加波沙朵和一种或多种抗炎化合物的组合用于治疗炎性疾病的用途。本发明还涉及包含加波沙朵和一种或多种抗炎化合物的药物组合物。本发明还涉及一种治疗疾病的方法，其中增加了一种或多种炎症标志物，其包括向有需要的受试者施用治疗有效量的增强GABA A能神经传递的化合物。

7. 发明申请

US20050137222A1 Treatment of insomnia in human patients 审中-公开
标题翻译：治疗人类失眠症患者
公开(公告)号：US20050137222A1
公开(公告)日：2005-06-23
申请号：US11014019
申请日：2004-12-15
申请人： Bjarke Ebert , Jonas Lundahl
发明人： Bjarke Ebert , Jonas Lundahl
IPC分类号： A61K31/4745
CPC分类号： A61K31/4745
摘要： The present invention concerns a method for treating insomnia in a human subject in need thereof by administering to said subject an amount of gaboxadol per day, said amount being effective for the treatment of insomnia. In various preferred embodiments, the effective amount is from 5 to 15 mg gaboxadol in oral dosage form, administered from one hour before up until bedtime.
摘要翻译：本发明涉及一种在有需要的人类受试者中通过向所述受试者施用一天量的加波沙朵来治疗失眠的方法，所述量对于治疗失眠是有效的。在各种优选实施方案中，有效量为口服剂型5至15mg加波沙朵，从上至上服1小时。

8. 发明申请

US20100093787A1 TREATMENT OF IMPAIRED RESPIRATORY FUNCTION WITH GABOXADOL 审中-公开
标题翻译：用GABOXADOL治疗有害呼吸功能
公开(公告)号：US20100093787A1
公开(公告)日：2010-04-15
申请号：US12635727
申请日：2009-12-11
申请人： Jonas Lundahl , Bjarke Ebert , Jan Hedner
发明人： Jonas Lundahl , Bjarke Ebert , Jan Hedner
IPC分类号： A61K31/437 , A61P25/20
CPC分类号： A61K31/424
摘要： The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day.
摘要翻译：本发明涉及一种治疗患有睡眠呼吸暂停（例如中枢性睡眠呼吸暂停或阻塞性睡眠呼吸暂停）的人类患者的受损呼吸功能的方法，包括每天向所述患者施用有效量的加波沙朵。

9. 发明申请

US20090203731A1 TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS 审中-公开
标题翻译：治疗呕吐和其他有害疾病
公开(公告)号：US20090203731A1
公开(公告)日：2009-08-13
申请号：US12389764
申请日：2009-02-20
申请人： Connie Sanchez , Bjarke Ebert
发明人： Connie Sanchez , Bjarke Ebert
IPC分类号： A61K31/437 , A61P25/00
CPC分类号： A61K31/4745
摘要： The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin.
摘要翻译：本发明涉及加波沙朵用于制备治疗抑郁症的药物组合物的用途。此外，它涉及使用加波沙朵来制备与5-羟色胺再摄取抑制剂或任何其它引起细胞外5-羟色胺水平升高的化合物组合使用的药物组合物。

10. 发明申请

US20050234093A1 Treatment of depression and other affective disorders 审中-公开
标题翻译：治疗抑郁症等情感障碍
公开(公告)号：US20050234093A1
公开(公告)日：2005-10-20
申请号：US11020632
申请日：2004-12-22
申请人： Connie Sanchez , Bjarke Ebert
发明人： Connie Sanchez , Bjarke Ebert
IPC分类号： A61K31/4745
CPC分类号： A61K31/4745
摘要： The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin.
摘要翻译：本发明涉及加波沙朵用于制备治疗抑郁症的药物组合物的用途。此外，它涉及使用加波沙朵来制备与5-羟色胺再摄取抑制剂或任何其它引起细胞外5-羟色胺水平升高的化合物组合使用的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式